Carrie Smith Cox, President of Schering-Plough, dumped 900,000 shares of SGP stock last year worth $28 million, shortly before the Vytorin trial scandal erupted in the press.
The questions about the delayed trial data even resulted in a Congressional inquiry.
Today Schering admitted there was no statistically significant difference between treatment groups on the primary endpoint and the stock dropped to $27.
Stock has now dropped close to 8%, to $25.61. This means Carrie Cox's received about $5 million more when she sold, than she would have made selling right now.
Comments